Oil-based adjuvants

Patent metadata

Field	Value
Publication number	US-10117921-B2
Application number	US-201414491414-A
Country	US
Kind code	B2
Filing date	Sep 19, 2014
Priority date	Sep 19, 2013
Publication date	Nov 6, 2018
Grant date	Nov 6, 2018

Abstract

The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

First claim

The invention claimed is:

1. An immunogenic composition comprising an effective amount of a Foot-and-Mouth Disease Virus (FMDV) antigen and an adjuvant formulation comprising an oily phase and an aqueous phase, a polycationic carrier, and a CpG containing immunostimulatory oligonucleotide, wherein the vaccine is a water-in-oil emulsion.

2. The immunogenic composition of claim 1 wherein the adjuvant formulation further comprises an aluminum hydroxide gel.

3. The immunogenic composition of claim 1 , wherein the polycationic carrier is DEAE dextran.

4. The immunogenic composition of claim 1 , wherein the Foot-and-Mouth Disease Virus antigen is genetically modified.

5. The immunogenic composition of claim 4 , wherein the Foot-and-Mouth Disease Virus antigen is a leaderless virus.

6. The immunogenic composition of claim 4 , wherein the Foot-and-Mouth Disease Virus antigen expresses one or more FMDV structural proteins of a serotype selected from the group consisting of A, C, O, Asia1, SAT1, SAT2, or SAT3.

7. The immunogenic composition of claim 6 , wherein the Foot-and-Mouth Disease virus antigen comprises antigens from multiple FMDV serotypes.

8. A method of protecting a bovine from FMDV infection comprising administering to said bovine the immunogenic composition according to claim 1 .

9. The composition according to claim 3 , wherein the CpG containing immunostimulatory oligonucleotide is present in the amount of about 50 to about 400 μg per dose and DEAE Dextran is present in the amount of about 10 to about 300 mg per dose.

10. The composition according to claim 9 wherein the CpG containing immunostimulatory oligonucleotide is present in the amount of about 100 to about 250 μg per dose and DEAE Dextran is present in the amount of about 50 to about 200 mg per dose.

11. The composition according to claim 3 , wherein the oil is a mineral oil.

12. The composition of claim 11 , wherein the CpG containing immunostimulatory oligonucleotide is present in the amount of about 100 to about 250 μg per dose and DEAE Dextran is present in the amount of about 50 to about 200 mg per dose.

13. The composition according to claim 12 wherein the CpG containing immunostimulatory oligonucleotide is present in the amount of about 100 μg per dose and DEAE Dextran is present in the amount of about 100 mg per dose.

14. A method of protecting a bovine from FMDV infection comprising administering to said bovine the immunogenic composition according to claim 12 .

15. A method of protecting a bovine from FMDV infection comprising administering to said bovine the immunogenic composition according to claim 13 .

Assignees

• Zoetis Services Llc

Inventors

• Dominowski Paul Joseph
• Foss Dennis L
• Gallo Guillermo
• Hardham John Morgan
• Krebs Richard Lee
• Lightle Sandra Ann Marie
• Mahan Suman
• Mediratta Sangita
• Mohr Kaori
• Mwangi Duncan
• Rai Sharath K
• Salmon Sarah A
• Vora Shaunak
• Wilmes Lauren

Classifications

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/10

  Antimycotics · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P33/14

  Ectoparasiticides, e.g. scabicides · CPC title